Drug intelligence / Profile preview

Tau2

Development stage: Phase 2

Overview

Tau2 is an investigational product being evaluated in the Alzheimer's Tau Platform (ATP) master protocol (NCT06957418). It is a tau-directed therapy aimed at reducing brain tau deposition and slowing disease progression in adults aged 50-80 with late preclinical or early prodromal Alzheimer's disease. The trial assesses Tau2 alone or in combination with an anti-amyloid monoclonal antibody.

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on Tau2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tau2.

Explore the full profile